Key facts
- It has raised $6.9M; the latest was Later Stage VC ($4.4M) in Mar 2026.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Phoreus Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Phoreus Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phoreus Biotech
Developer of medical technology designed to increase efficacy in creating and delivering novel vaccines. The company offers customized branched amphipathic peptide capsules along with proprietary antisense oligonucleotide technology to provide stability in circulation and reduce off-target accumulation for a novel non-toxic cancer therapy, enabling the healthcare industry to increase the creation of cancer therapies and alternative antibiotics.
- Sector
- Healthcare
- HQ
- Olathe, KS, United States
- Founded
- 2018
- Employees
- 10
- Website
- phoreusbiotech.com/
- Ownership
- Privately Held (backing)
Phoreus Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phoreus Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phoreus Biotech in its N-PORT filings yet. We sweep new filings monthly.